Series C · nearly CNY 500M · July 2026 · Biotech & pharma · China
Cell therapy from chemically induced iPSCs (Parkinson's; NouvSight001 for retinitis pigmentosa).
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07 | Series C | nearly CNY 500M | — | 21jingji.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-11.
OMass Therapeutics, based at ARC Oxford (UK); site sections cover science, technology, pipeline and news.
RxActuator makes a pet-hospital-grade wearable infusion pump (Mini-Infuser) for pain management and drug delivery during pet recovery at home.
UNSW Sydney spinout developing a DNA sequencing platform based on a plasmonic nanoantenna that reads native DNA molecules without amplification.
Develops oligonucleotide (siRNA) therapies designed to reach and enter the specific cells that drive disease, starting with programs in FSHD muscular dystrophy and heart failure.
AgTech company developing climate-resilient cereal seed varieties (salt-tolerant wheat, heat-resistant and nitrogen-efficient seeds) using its SeedAX biotech platform for trait…
NuSynth is an R&D-led process innovation platform that redesigns synthesis routes for complex chemistry (pharmaceutical and electronic chemicals) using fewer steps, safer…
